Capital News

Pemphigus Vulgaris Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

 Breaking News
  • No posts were found

Pemphigus Vulgaris Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

March 24
18:28 2020
Pemphigus Vulgaris Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

(Albany, US) DelveInsight has launched a new report on Pemphigus Vulgaris Market Insights, Epidemiology and Market Forecast-2030

“Pemphigus Vulgaris Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Pemphigus Vulgaris market. A detailed picture of the Pemphigus Vulgaris pipeline landscape is provided, which includes the disease overview and Pemphigus Vulgaris treatment guidelines. The assessment part of the report embraces in-depth Pemphigus Vulgaris commercial assessment and clinical assessment of the Pemphigus Vulgaris pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pemphigus Vulgaris collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Pemphigus Vulgaris (PV) is a rare, potentially fatal, autoimmune and intraepithelial disease characterized by flaccid blisters and erosions of the skin, and also mucous membrane and histologically by acantholysis. It is mediated by circulating desmoglein-reactive autoantibodies, directed against keratinocyte cell surfaces.

 

 

Request for :- Pemphigus Vulgaris free sample page

 

Pemphigus Vulgaris Overview

“Pemphigus Vulgaris Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Pemphigus Vulgaris market. A detailed picture of the Pemphigus Vulgaris pipeline landscape is provided, which includes the disease overview and Pemphigus Vulgaris treatment guidelines. The assessment part of the report embraces in-depth Pemphigus Vulgaris commercial assessment and clinical assessment of the Pemphigus Vulgaris pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pemphigus Vulgaris collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Pemphigus Vulgaris Analytical Perspective by DelveInsight

  • In-depth Pemphigus Vulgaris Commercial Assessment of products 

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

  • Pemphigus Vulgaris Clinical Assessment of products 

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

 

Report key facts:- 

1. The annual frequency of PV has been reported between 0.76 and 16.1 per million population, depending on the geographical area and the ethnicity. (Didona et al.)

2. In a recent analysis on the US population, an overall standardized point prevalence of 5.2 cases per 100,000 adults has been reported. (Wertenteil et al.)

3. Among the EU5 countries, Germany has the highest prevalent population of PV, followed by France. Spain has the lowest prevalent cases.

“The increase in Market size is a direct consequence of increasing prevalent population of Pemphigus Vulgaris (PV) patients in the 7MM”

 

 Table of Content

 

1. Report Introduction

 

2. Pemphigus Vulgaris 

 

3. Pemphigus Vulgaris Current Treatment Patterns

 

4. Pemphigus Vulgaris – DelveInsight’s Analytical Perspective

 

5. Therapeutic Assessment

 

6. Pemphigus Vulgaris Late Stage Products (Phase-III)

 

7. Pemphigus Vulgaris Mid Stage Products (Phase-II)

 

8. Early Stage Products (Phase-I)

 

9. Pre-clinical Products and Discovery Stage Products

 

10. Inactive Products

 

11. Dormant Products

 

12. Pemphigus Vulgaris Discontinued Products

 

13. Pemphigus Vulgaris Product Profiles

 

14. Pemphigus Vulgaris Key Companies

 

15. Pemphigus Vulgaris Key Products

 

16. Dormant and Discontinued Products

 

17. Pemphigus Vulgaris Unmet Needs

 

18. Pemphigus Vulgaris Future Perspectives

 

19. Pemphigus Vulgaris Analyst Review  

 

20. Appendix

 

21. Report Methodology

 

21.1. Secondary Research

 

21.2. Expert Panel Validation 

22. About Delveinsight 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/